Search clinical trials for: tyrosine kinase inhibitor

Total 67897 results

The First Affiliated Hospital of Guangzhou Medical...

Recruiting

Osimertinib as Neoadjuvant Therapy in Patients With Resectable Stage II-IIIB EGFR-mutated Lung Squamous Cell Carcinoma (GALAXY-02)

Carcinoma, Squamous Cell | Lung Cancer

China
Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC
Zhejiang Genfleet Therapeutics Co., Ltd.

Recruiting

A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

Large B-cell Lymphoma

China
Convalife (Shanghai) Co., Ltd.

Not yet recruiting

Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis
Korean Society of Hematology

Not yet recruiting

A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia (AsterA)

Chronic Myeloid Leukemia, Chronic Phase
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma
National Cancer Center, China

Not yet recruiting

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations (EGFR)

NSCLC
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle Deregulation

China
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Not yet recruiting

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
China Medical University Hospital

Recruiting

Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

Hepatocellular Carcinoma

Taiwan
Fudan University

Not yet recruiting

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Triple-negative Breast Cancer
AstraZeneca
Daiichi Sankyo

Not yet recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)

Non-small Cell Lung Cancer

China, Taiwan, Korea, Republic of, Australia
H. Lee Moffitt Cancer Center and Research Institute
BeiGene, Ltd.

Recruiting

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Follicular Lymphoma | Marginal Zone Lymphoma | B-Cell Lymphoma

United States
Fudan University

Recruiting

A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma | Maintenance Therapy

China
National University Hospital, Singapore

Recruiting

Ma-Spore ALL 2020 Study

B Lymphoblastic Leukemia

Malaysia, Singapore
Inhye Ahn
Loxo Oncology, Inc.

Recruiting

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Etnova Therapeutics Corp.

Recruiting

A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma | Liver Cancer

Korea, Republic of
Fudan University

Not yet recruiting

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Lung Cancer | Minimal Residual Disease | EGFR Gene Mutation
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)

Biliary Tract Cancer | Gemox Chemotherapy

China
Taizhou Hospital

Not yet recruiting

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Lung Cancer, Nonsmall Cell
Ascentage Pharma Group Inc.

Recruiting

A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

CLL/SLL

China
National Cancer Institute (NCI)

Not yet recruiting

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia
Tianjin Hemay Pharmaceutical Co., Ltd

Recruiting

A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer

Breast Cancer

China
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Not yet recruiting

Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Philadelphia Chromosome-Positive

United States
Medical College of Wisconsin

Not yet recruiting

Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)

Non Small Cell Lung Cancer

United States
Suzhou Genhouse Bio Co., Ltd.

Recruiting

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

Non-Small Cell Lung Cancer With EGFR Mutation

China
Guangzhou Medical University

Recruiting

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Leptomeningeal Metastasis

China
Merck Sharp & Dohme LLC

Not yet recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Non-small Cell Lung Cancer (NSCLC)
Massachusetts General Hospital
Boehringer Ingelheim; Incyte Corporation

Recruiting

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Cholangiocarcinoma | Advanced Solid Tumor | Metastatic Solid Tumor | Unresectable Solid Tumor

United States
Janssen Cilag S.A.S.

Not yet recruiting

Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia (QOLIBRI)

Leukemia, Lymphocytic, Chronic, B-Cell
Pfizer

Not yet recruiting

A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).

Chronic Leukemia Myelogenous
Mayo Clinic

Not yet recruiting

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Chronic Graft Versus Host Disease | Hematopoietic and Lymphatic System Neoplasm

United States
Sahar Mohammed Gad

Not yet recruiting

Chronic Kidney Disease Patient in Chronic Myloied Leukemia

Chronic Myeloid Leukemia in Remission
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

AML | Refractory | Relapsed

China
Shouyao Holdings (Beijing) Co. LTD

Not yet recruiting

A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Non-small Cell Lung Cancer

China
C. Babis Andreadis
Eli Lilly and Company; Genentech, Inc.; Adaptive Biotechnologies

Not yet recruiting

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Recruiting

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Chronic Myeloid Leukemia

United States
University of California, Irvine

Recruiting

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia

Chronic Myeloid Leukemia | Chronic Phase Chronic Myelogenous Leukemia

United States
University of Michigan Rogel Cancer Center

Recruiting

Gilteritinib for the Treatment of ALK NSCLC

Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
Ocular Therapeutix, Inc.
Duke University; Fortrea

Recruiting

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
University Hospital, Caen

Not yet recruiting

Is Ibrutinib-related Atrial Fibrillation Dose Dependent

Atrial Fibrillation | Hematological Malignancy

France
Children's Hospital of Soochow University

Recruiting

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML (GMCAII)

Acute Myeloid Leukemia | AML, Childhood

China
Uma Borate

Recruiting

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 Mutation

United States
AstraZeneca
Yghea

Recruiting

Acalabrutinib Real World Italian obSErvational Study -ARISE (ARISE)

Chronic Lymphocytic Leukemia

Italy
AstraZeneca

Not yet recruiting

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations (NEOLA)

Lung Cancer

Thailand, Vietnam, Korea, Republic of, India, China, Taiwan, United States, Israel, Spain, Turkey
University Health Network, Toronto

Not yet recruiting

A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T (ZanTisle)

Large B-cell Lymphoma
Gene Solutions

Recruiting

Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.

Non Small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Stage IIIC Non-Small Cell Lung Cancer | Tyrosine Kinase Inhibitors

Vietnam
National Cancer Institute (NCI)

Not yet recruiting

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

Neoplasms

United States
Mayo Clinic

Recruiting

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Hematopoietic and Lymphoid System Neoplasm

United States
Peking Union Medical College
Peking University Hospital of Stomatology

Recruiting

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Precision Therapy | Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma | Neoadjuvant or Conversion Therapy

China

3

Subscribe